drugset / Trial / NCT03448042
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
Timeline
- Start
- 2018-06-06
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Runimotamab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |